From the Press

New personalised approaches to depression will either predict when a person is at risk to stop the condition in its tracks or target the illness with the optimum drug.

This week in our Startup Spotlight blog series is our 2021 XTC Healthcare Category Winner – Genetika+: Precision Medicine with “Brain-in-a-Dish”!

The pathway to effective treatment of MDD may be improved by multifaceted diagnostic tools, including but not limited to brain-in-a-dish technology.

NeuroKaire demonstrates high accuracy in predicting drug response in patients suffering from major depressive disorder

Through an Israeli startup's tech, physicians will soon be able to give patients a list of the antidepressants that would work best for them.

Kahn-Sagol-Maccabi (KSM) and Genetika+ form a research partnership to develop and validate AI that personalizes and speeds up an optimal depression treatment

ממחשוב קוונטי ועד צבעי מאכל, ומדיבוב סרטים עד גיוס עובדים. כמדי שנה, כתבי TheMarker בוחרים ב-20 חברות טכנולוגיה צעירות עם רעיונות גדולים

Find out more about the extraordinary work happening at Genetika+ as we bring precision medicine into practice to optimize depression treatment

Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market

Genetika+ personalizes treatment in the mental health space, initially focusing on depression. The Genetika+ platform uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Co-Sponsored by J.P. Morgan and Johnson & Johnson, Genetika+ Gives Award Winning Presentation

Biomed Israel hosts leaders in the field to speak how AI and machine learning tools and techniques change the way we discover and develop drugs.

Science Abroad hosts exposure workshop for biotech professionals all over Israel

How did a female-led startup from the MC18 Israel cohort turn their MassChallenge experience into a $10 million Series A funding round? Learn more about Genetika+ and its co-founders, Talia Cohen Solal and Daphna Laifenfeld, in our most recent case study.

Depression, historically, has been treated by trial and error until a therapy with a positive and stable outcome can be identified. Genetika+ is changing that with precision, personalized testing that enables the right antidepressant to be selected for patients the first time.

Proceeds to fund clinical trials and scale up in the U.S. market. New investment underscores the company’s promise to transform precision medicine and mental health.

A successful female entrepreneur, Talia Cohen Solal is an extremely driven, compassionate, and curious individual. As the CEO & Co-Founder of Genetika+, a biotech start-up specialized in developing new tools for personalized medicine in major depression, she is advancing treatment in a much-needed space. In this interview, she speaks on a range of topics – from a unique scientific approach to depression treatment, to her journey from academic to entrepreneur, from challenges faced in the industry, to her passion for entrepreneurship. Here are some excerpts from the interview.

Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the healthcare sector. This time, you get to discover 5 hand-picked startups tackling depression and mental health.

The company developed a platform for 3D printing of tissues and organs. Genetika+, which developed a personalized technology for digital health took second place; winners awarded monetary prizes and office space.

Avon Products, Inc. Reveals Winner of Women Startup Competition.